Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Revenue (2018 - 2025)

Serina Therapeutics (SER) has disclosed Revenue for 8 consecutive years, with $130000.0 as the latest value for Q2 2025.

  • Quarterly Revenue rose 154.9% to $130000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $130000.0 through Dec 2025, up 132.14% year-over-year, with the annual reading at $130000.0 for FY2025, 132.14% up from the prior year.
  • Revenue hit $130000.0 in Q2 2025 for Serina Therapeutics, up from -$14000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $3.1 million in Q4 2023 to a low of -$14000.0 in Q4 2024.
  • Historically, Revenue has averaged $206882.4 across 5 years, with a median of $24000.0 in 2021.
  • Biggest five-year swings in Revenue: soared 38487.5% in 2023 and later plummeted 100.45% in 2024.
  • Year by year, Revenue stood at $27000.0 in 2021, then tumbled by 70.37% to $8000.0 in 2022, then skyrocketed by 38487.5% to $3.1 million in 2023, then plummeted by 100.45% to -$14000.0 in 2024, then skyrocketed by 1028.57% to $130000.0 in 2025.
  • Business Quant data shows Revenue for SER at $130000.0 in Q2 2025, -$14000.0 in Q4 2024, and $14000.0 in Q3 2024.